;PMID: 9024310
;source_file_1408.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:44..138] = [t:44..138]
;2)section:[e:142..244] = [t:142..244]
;3)section:[e:248..314] = [t:248..314]
;4)sentence:[e:318..468] = [t:318..468]
;5)sentence:[e:469..605] = [t:469..605]
;6)sentence:[e:606..762] = [t:606..762]
;7)sentence:[e:763..1010] = [t:763..1010]
;8)sentence:[e:1011..1172] = [t:1011..1172]
;9)sentence:[e:1173..1343] = [t:1173..1343]
;10)sentence:[e:1344..1411] = [t:1344..1411]
;11)sentence:[e:1412..1584] = [t:1412..1584]
;12)section:[e:1588..1632] = [t:1588..1632]

;section 0 Span:0..39
;Gastroenterology  1997 Feb;112(2):561-6
(SEC
  (FRAG (VB:[0..16] Gastroenterology) (CD:[18..22] 1997)
        (-LRB-:[23..31] Feb;112-LRB-) (CD:[31..32] 2) (-RRB-:[32..33] -RRB-)
        (CD:[33..37] :561) (HYPH:[37..38] -) (CD:[38..39] 6)))

;sentence 1 Span:44..138
;Multiple hyperplastic polyps in the stomach: evidence for clonality and 
;neoplastic potential.
;[53..87]:malignancy:"hyperplastic polyps in the stomach"
(SENT
  (NP-HLN
    (NP
      (NP (JJ:[44..52] Multiple) (JJ:[53..65] hyperplastic)
          (NNS:[66..72] polyps))
      (PP-LOC (IN:[73..75] in)
        (NP (DT:[76..79] the) (NN:[80..87] stomach))))
    (::[87..88] :)
    (NP
      (NP (NN:[89..97] evidence))
      (PP (IN:[98..101] for)
        (NP
          (NP (NN:[102..111] clonality))
          (CC:[112..115] and)
          (NP (JJ:[117..127] neoplastic) (NN:[128..137] potential)))))
    (.:[137..138] .)))

;section 2 Span:142..244
;Dijkhuizen SM, Entius MM, Clement MJ, Polak MM, Van den Berg FM, Craanen ME, 
;Slebos RJ, Offerhaus GJ.
(SEC
  (FRAG (NNP:[142..152] Dijkhuizen) (NNP:[153..155] SM) (,:[155..156] ,)
        (NNP:[157..163] Entius) (NNP:[164..166] MM) (,:[166..167] ,)
        (NNP:[168..175] Clement) (NNP:[176..178] MJ) (,:[178..179] ,)
        (NNP:[180..185] Polak) (NNP:[186..188] MM) (,:[188..189] ,)
        (NNP:[190..193] Van) (NNS:[194..197] den) (NNP:[198..202] Berg)
        (NNP:[203..205] FM) (,:[205..206] ,) (NNP:[207..214] Craanen)
        (NNP:[215..217] ME) (,:[217..218] ,) (NNP:[220..226] Slebos)
        (NNP:[227..229] RJ) (,:[229..230] ,) (NNP:[231..240] Offerhaus)
        (NNP:[241..244] GJ.)))

;section 3 Span:248..314
;Department of Pathology, University of Amsterdam, The Netherlands.
(SEC
  (FRAG (NNP:[248..258] Department) (IN:[259..261] of)
        (NNP:[262..271] Pathology) (,:[271..272] ,) (NNP:[273..283] University)
        (IN:[284..286] of) (NNP:[287..296] Amsterdam) (,:[296..297] ,)
        (DT:[298..301] The) (NNP:[302..313] Netherlands) (.:[313..314] .)))

;sentence 4 Span:318..468
;The origin and neoplastic potential of gastric epithelial polyps remains an
;area  of great interest, and treatment choices are a topic of controversy.
;[357..382]:malignancy:"gastric epithelial polyps"
(SENT
  (S
    (S
      (NP-SBJ
        (NP
          (NP (DT:[318..321] The) (NN:[322..328] origin))
          (CC:[329..332] and)
          (NP (JJ:[333..343] neoplastic) (NN:[344..353] potential)))
        (PP (IN:[354..356] of)
          (NP (JJ:[357..364] gastric) (JJ:[365..375] epithelial)
              (NNS:[376..382] polyps))))
      (VP (VBZ:[383..390] remains)
        (NP-PRD
          (NP (DT:[391..393] an) (NN:[394..398] area))
          (PP (IN:[400..402] of)
            (NP (JJ:[403..408] great) (NN:[409..417] interest))))))
    (,:[417..418] ,) (CC:[419..422] and)
    (S
      (NP-SBJ (NN:[423..432] treatment) (NNS:[433..440] choices))
      (VP (VBP:[441..444] are)
        (NP-PRD
          (NP (DT:[445..446] a) (NN:[447..452] topic))
          (PP (IN:[453..455] of)
            (NP (NN:[456..467] controversy))))))
    (.:[467..468] .)))

;sentence 5 Span:469..605
;This report  describes a patient diagnosed with three concurrent hyperplastic
;gastric polyps  that were studied for genetic alterations.
;[534..561]:malignancy:"hyperplastic gastric polyps"
(SENT
  (S
    (NP-SBJ (DT:[469..473] This) (NN:[474..480] report))
    (VP (VBZ:[482..491] describes)
      (NP
        (NP (DT:[492..493] a) (NN:[494..501] patient))
        (VP (VBN:[502..511] diagnosed)
          (NP (-NONE-:[511..511] *))
          (PP (IN:[512..516] with)
            (NP
              (NP (CD:[517..522] three) (JJ:[523..533] concurrent)
                 (JJ:[534..546] hyperplastic) (JJ:[547..554] gastric)
                 (NNS:[555..561] polyps))
              (SBAR
                (WHNP-1 (WDT:[563..567] that))
                (S
                  (NP-SBJ-1 (-NONE-:[567..567] *T*))
                  (VP (VBD:[568..572] were)
                    (VP (VBN:[573..580] studied)
                      (NP-1 (-NONE-:[580..580] *))
                      (PP (IN:[581..584] for)
                        (NP (JJ:[585..592] genetic) (NNS:[593..604] alterations))))))))))))
    (.:[604..605] .)))

;sentence 6 Span:606..762
;The polyps were investigated for  alterations in the K-ras oncogene and the
;p53 tumor suppressor gene and for  p21WAF1/Cip1 and MDM2 protein
;overexpression.
;[610..616]:malignancy:"polyps"
;[659..664]:gene-rna:"K-ras"
;[682..685]:gene-rna:"p53"
;[717..724]:gene-protein:"p21WAF1"
;[725..729]:gene-protein:"Cip1"
;[734..738]:gene-protein:"MDM2"
(SENT
  (S
    (NP-SBJ-1 (DT:[606..609] The) (NNS:[610..616] polyps))
    (VP (VBD:[617..621] were)
      (VP (VBN:[622..634] investigated)
        (NP-1 (-NONE-:[634..634] *))
        (PP
          (PP (IN:[635..638] for)
            (NP
              (NP (NNS:[640..651] alterations))
              (PP-LOC (IN:[652..654] in)
                (NP
                  (NP (DT:[655..658] the) (NN:[659..664] K-ras)
                      (NN:[665..673] oncogene))
                  (CC:[674..677] and)
                  (NP (DT:[678..681] the) (NN:[682..685] p53)
                    (NML (NN:[686..691] tumor) (NN:[692..702] suppressor))
                    (NN:[703..707] gene))))))
          (CC:[708..711] and)
          (PP (IN:[712..715] for)
            (NP
              (NP (NN:[717..724] p21WAF1) (SYM:[724..725] /)
                  (NN:[725..729] Cip1)
                (NML-2 (-NONE-:[729..729] *P*)))
              (CC:[730..733] and)
              (NP (NN:[734..738] MDM2)
                (NML-2 (NN:[739..746] protein) (NN:[747..761] overexpression))))))))
    (.:[761..762] .)))

;sentence 7 Span:763..1010
;In addition, loss of  heterozygosity at several loci that are frequently
;involved in human cancer was  analyzed, microsatellite instability, a
;hallmark of the "mutator" phenotype, was  determined, and Epstein-Barr virus
;infection was investigated.
;[776..799]:variation-type:"loss of  heterozygosity"
(SENT
  (S
    (S
      (PP (IN:[763..765] In)
        (NP (NN:[766..774] addition)))
      (,:[774..775] ,)
      (NP-SBJ-4
        
        (NP (NN:[776..780] loss))
        (PP (IN:[781..783] of)
          (NP (NN:[785..799] heterozygosity)))
        (PP-LOC (IN:[800..802] at)
          (NP
            (NP (JJ:[803..810] several) (NNS:[811..815] loci))
            (SBAR
              (WHNP-3 (WDT:[816..820] that))
              (S
                (NP-SBJ-3 (-NONE-:[820..820] *T*))
                (VP (VBP:[821..824] are)
                  (ADVP-TMP (RB:[825..835] frequently))
                  (VP (VBN:[836..844] involved)
                    (NP-3 (-NONE-:[844..844] *))
                    (PP-CLR (IN:[845..847] in)
                      (NP (JJ:[848..853] human) (NN:[854..860] cancer))))))))))
      (VP (VBD:[861..864] was)
        (VP (VBN:[866..874] analyzed)
          (NP-4 (-NONE-:[874..874] *)))))
    (,:[874..875] ,)
    (S
      (NP-SBJ-2
        (NP (NN:[876..890] microsatellite) (NN:[891..902] instability))
        (,:[902..903] ,)
        (NP
          (NP (DT:[904..905] a) (NN:[906..914] hallmark))
          (PP (IN:[915..917] of)
            (NP (DT:[918..921] the) (``:[922..923] ") (NN:[923..930] mutator)
                ('':[930..931] ") (NN:[932..941] phenotype)))))
      (,:[941..942] ,)
      (VP (VBD:[943..946] was)
        (VP (VBN:[948..958] determined)
          (NP-2 (-NONE-:[958..958] *)))))
    (,:[958..959] ,) (CC:[960..963] and)
    (NP-SBJ-1
      (NML (NNP:[964..971] Epstein) (HYPH:[971..972] -) (NNP:[972..976] Barr))
      (NN:[977..982] virus) (NN:[983..992] infection))
    (VP (VBD:[993..996] was)
      (VP (VBN:[997..1009] investigated)
        (NP-1 (-NONE-:[1009..1009] *))))
    (.:[1009..1010] .)))

;sentence 8 Span:1011..1172
;All separate  areas from the three independent polyps harbored the same
;activating point  mutation in codon 12 of the K-ras oncogene, indicating a
;clonal origin.
;[1058..1064]:malignancy:"polyps"
;[1094..1109]:variation-type:"point  mutation"
;[1113..1121]:variation-location:"codon 12"
;[1129..1134]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1011..1014] All) (JJ:[1015..1023] separate)
          (NNS:[1025..1030] areas))
      (PP (IN:[1031..1035] from)
        (NP (DT:[1036..1039] the) (CD:[1040..1045] three)
            (JJ:[1046..1057] independent) (NNS:[1058..1064] polyps))))
    (VP (VBD:[1065..1073] harbored)
      (NP (DT:[1074..1077] the) (JJ:[1078..1082] same)
          (VBG:[1083..1093] activating)
         (NN:[1094..1099] point) (NN:[1101..1109] mutation))
      (PP-LOC (IN:[1110..1112] in)
        (NP
          (NP (NN:[1113..1118] codon) (CD:[1119..1121] 12))
          (PP (IN:[1122..1124] of)
            (NP (DT:[1125..1128] the) (NN:[1129..1134] K-ras)
                (NN:[1135..1143] oncogene)))))
      (,:[1143..1144] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1144..1144] *))
        (VP (VBG:[1145..1155] indicating)
          (NP (DT:[1156..1157] a) (JJ:[1158..1164] clonal)
              (NN:[1165..1171] origin)))))
    (.:[1171..1172] .)))

;sentence 9 Span:1173..1343
;DNA  sequence alterations in p53 were not found, although high p53 protein
;levels  could be shown by immunohistochemistry in areas of carcinoma within
;the largest  polyp.
;[1202..1205]:gene-rna:"p53"
;[1236..1239]:gene-protein:"p53"
;[1307..1316]:malignancy:"carcinoma"
;[1337..1342]:malignancy:"polyp"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1173..1176] DNA) (NN:[1178..1186] sequence)
          (NNS:[1187..1198] alterations))
      (PP-LOC (IN:[1199..1201] in)
        (NP (NN:[1202..1205] p53))))
    (VP (VBD:[1206..1210] were) (RB:[1211..1214] not)
      (VP (VBN:[1215..1220] found)
        (NP-1 (-NONE-:[1220..1220] *))
        (,:[1220..1221] ,)
        (SBAR-ADV (IN:[1222..1230] although)
          (S
            (NP-SBJ-2 (JJ:[1231..1235] high) (NN:[1236..1239] p53)
                      (NN:[1240..1247] protein) (NNS:[1248..1254] levels))
            (VP (MD:[1256..1261] could)
              (VP (VB:[1262..1264] be)
                (VP (VBN:[1265..1270] shown)
                  (NP-2 (-NONE-:[1270..1270] *))
                  (PP-MNR (IN:[1271..1273] by)
                    (NP (NN:[1274..1294] immunohistochemistry)))
                  (PP-LOC (IN:[1295..1297] in)
                    (NP
                      (NP (NNS:[1298..1303] areas))
                      (PP (IN:[1304..1306] of)
                        (NP (NN:[1307..1316] carcinoma)))
                      (PP-LOC (IN:[1317..1323] within)
                        (NP (DT:[1324..1327] the) (JJS:[1328..1335] largest)
                            (NN:[1337..1342] polyp))))))))))))
    (.:[1342..1343] .)))

;sentence 10 Span:1344..1411
;No alterations in any of the other molecular markers were observed.
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1344..1346] No) (NNS:[1347..1358] alterations))
      (PP (IN:[1359..1361] in)
        (NP
          (NP (DT:[1362..1365] any))
          (PP (IN:[1366..1368] of)
            (NP (DT:[1369..1372] the) (JJ:[1373..1378] other)
                (JJ:[1379..1388] molecular) (NNS:[1389..1396] markers))))))
    (VP (VBD:[1397..1401] were)
      (VP (VBN:[1402..1410] observed)
        (NP-1 (-NONE-:[1410..1410] *))))
    (.:[1410..1411] .)))

;sentence 11 Span:1412..1584
;The  results strongly favor a clonal origin of the three independent gastric
;polyps  and support the notion that these hyperplastic polyps may carry a
;risk for  malignancy.
;[1481..1495]:malignancy:"gastric polyps"
;[1531..1550]:malignancy:"hyperplastic polyps"
(SENT
  (S
    (NP-SBJ (DT:[1412..1415] The) (NNS:[1417..1424] results))
    (ADVP (RB:[1425..1433] strongly))
    (VP
      (VP (VBP:[1434..1439] favor)
        (NP
          (NP (DT:[1440..1441] a) (JJ:[1442..1448] clonal)
              (NN:[1449..1455] origin))
          (PP (IN:[1456..1458] of)
            (NP (DT:[1459..1462] the) (CD:[1463..1468] three)
                (JJ:[1469..1480] independent)
               (JJ:[1481..1488] gastric) (NNS:[1489..1495] polyps)))))
      (CC:[1497..1500] and)
      (VP (VBP:[1501..1508] support)
        (NP (DT:[1509..1512] the) (NN:[1513..1519] notion)
          (SBAR (IN:[1520..1524] that)
            (S
              (NP-SBJ (DT:[1525..1530] these)
                 (JJ:[1531..1543] hyperplastic) (NNS:[1544..1550] polyps))
              (VP (MD:[1551..1554] may)
                (VP (VB:[1555..1560] carry)
                  (NP
                    (NP (DT:[1561..1562] a) (NN:[1563..1567] risk))
                    (PP (IN:[1568..1571] for)
                      (NP (NN:[1573..1583] malignancy)))))))))))
    (.:[1583..1584] .)))

;section 12 Span:1588..1632
;PMID: 9024310 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1588..1592] PMID) (::[1592..1593] :) (CD:[1594..1601] 9024310)
        (IN:[1602..1603] -LSB-) (NNP:[1603..1609] PubMed) (HYPH:[1610..1611] -)
        (JJ:[1612..1619] indexed) (IN:[1620..1623] for)
        (NNP:[1624..1632] MEDLINE-RSB-)))
